ArticleBioinformatics advances2026
THe Biom: a platform for visualization and exploration of cancer transcriptomic biomarkers identified by robust feature selection.
Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of robust transcriptomic biomarkers remains a key challenge in oncology. To tackle this problem, hybrid ensemble feature selection (HEFS) methods have been developed to improve the stability of gene signatures by combining multiple algorithms and data perturbations. However, their results are often difficult to explore, interpret and reuse. To bridge this gap, we developed THe Biom (TCGA HEFS Biomarkers), an interactive application for visualization and comparative analysis of gene signatures across tumor stages and cancer types. The platform enables users to examine cancer-specific biomarkers, track changes across disease progression, and highlight shared features among signatures. THe Biom was built using previous HEFS analyses of six TCGA cancers across stages I to IV, and additional signatures can be added by users.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.